A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC).

Nobuaki Matsubara,Daniel Peter Petrylak,Hiroyuki Nishiyama,Wen-Pin Su,Jae-Lyun Lee,Jian-Ri Li,Richard A. Walgren,Oday Hamid,Annamaria Zimmermann,Katherine M Bell-McGuinn,Ling Gao,Gosuke Homma,Ikuo Yana,Thomas Powles

A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC).

2018

Nobuaki Matsubara
Daniel Peter Petrylak
Hiroyuki Nishiyama
Wen-Pin Su
Jae-Lyun Lee
Jian-Ri Li
Richard A. Walgren
Oday Hamid
Annamaria Zimmermann
Katherine M Bell-McGuinn
Ling Gao
Gosuke Homma
Ikuo Yana
Thomas Powles

4542Background: RANGE (NCT02426125) is a global, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of RAM in combination with DOC in patients (pts) wit...

Keywords:

Refractory
Ramucirumab
Metastatic Urothelial Carcinoma
Subgroup analysis
Phases of clinical research
Oncology
Pathology
Population
Docetaxel
Internal medicine
Medicine
platinum resistance
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations